吡啶[2,3-D]嘧啶-7-胺 | 76587-31-0

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: 吡啶[2,3-D]嘧啶-7-胺
• 英文名称: Pyrido[2,3-d]pyrimidin-7-amine
• CAS: 76587-31-0
• 化学式: C₇H₆N₄
• mdl: MFCD10000614
• 分子量: 146.15
• InChiKey: SZWAMIJZBXMYDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

文献信息

• Novel dihydropyridinone compounds
  申请人：——

  公开号：US20040122029A1

  公开（公告）日：2004-06-24

  Disclosed are novel dihydropridinone compounds that are selective inhibitors of both KDR and FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon lung and prostate tumors. Also, disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

  本文披露了一种新型二氢吡啶酮化合物，它们是KDR和FGFR激酶的选择性抑制剂。这些化合物及其药用盐是抗增殖剂，可用于治疗或控制实体肿瘤，特别是乳腺、结肠、肺和前列腺肿瘤。此外，还披露了含有这些化合物的药物组合物和治疗癌症的方法。
• Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
  申请人：——

  公开号：US20040224958A1

  公开（公告）日：2004-11-11

  This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula (I) and Formula (II) where W is NH, S, SO, or SO 2 , R 1 includes phenyl and substituted phenyl, R 2 includes alkyl and cycloalkyl, R 3 includes alkyl and hydrogen, R 8 and R 9 include hydrogen and alkyl, and Z is carboxy. This invention also provide pharmaceutical formulations comprising a compound of Formula (I or II) together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. 1

  这项发明提供了对治疗细胞增殖性疾病（如癌症和再狭窄）有用的吡啶吡嘧啶和4-氨基吡嘧啶。我们现在发现了一组7,8-二氢-2（氨基和硫）吡啶嘧啶和2,4-二氨基吡嘧啶，它们是细胞周期依赖性激酶（cdk）和生长因子介导的激酶的有效抑制剂。这些化合物易于合成，并且可以通过多种途径（包括口服）给药，具有足够的生物利用度。该发明提供了式（I）和式（II）的化合物，其中W为NH、S、SO或SO2，R1包括苯基和取代苯基，R2包括烷基和环烷基，R3包括烷基和氢，R8和R9包括氢和烷基，Z为羧基。该发明还提供了含有式（I或II）化合物的制剂，与其一起使用的药用可接受载体、稀释剂或赋形剂。
• [EN] PYRIDOPYRIMIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES A BASE DE PYRIDOPYRIMIDINE
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2004063195A1

  公开（公告）日：2004-07-29

  The present invention provides compounds of formula (0): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (0) and provides methods of treating cancer comprising administering a compound of formula (0).

  本发明提供了一种通式为（0）的化合物，如本文中一般描述以及各类和子类中描述的那样。本发明还提供了包含通式为（0）的化合物的药物组合物，并提供了治疗癌症的方法，包括给予通式为（0）的化合物。
• Therapeutic agent for dermatitis
  申请人：——

  公开号：US20010056097A1

  公开（公告）日：2001-12-27

  The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents. The present invention relates to a therapeutic agent containing a compound represented by the following formula (I) or a pharmaceutically acceptable salt or hydrate thereof as an effective ingredient: 1 wherein R is hydrogen or a halogen. The therapeutic agent for dermatitis according to the present invention effectively and in a dose-dependent manner suppresses antigen-induced swelling in a mouse ear, a recognized animal model for atopic dermatitis, and suppresses the antigen-induced flare-up reaction in mice which occurred with the swelling reaction. In addition, no adverse reaction in the skin are observed.

  本发明提供了一种治疗皮炎，特别是治疗特应性皮炎的治疗剂，与例如类固醇类药物相比，该治疗剂非常安全，并且显示出很少的不良副作用。本发明涉及一种治疗剂，其包含以下式(I)所代表的化合物或其药学上可接受的盐或水合物作为有效成分：1其中R是氢或卤素。根据本发明的皮炎治疗剂能够有效地、剂量依赖地抑制小鼠耳朵抗原诱导的肿胀，这是一种被公认为特应性皮炎的动物模型，并且抑制了伴随肿胀反应发生的小鼠抗原诱导的红斑反应。此外，没有观察到皮肤的不良反应。
• Pyridopyrimidine kinase inhibitors
  申请人：Veach R. Darren

  公开号：US20050009849A1

  公开（公告）日：2005-01-13

  The present invention provides compounds of formula (0): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (0) and provides methods of treating cancer comprising administering a compound of formula (0).

  本发明提供公式（0）的化合物，如本文中所述的一般和各类和子类中所描述的。本发明还提供包括公式（0）化合物的制药组合物，并提供治疗癌症的方法，其中包括给予公式（0）的化合物。